Meriofert Pfs

Follicle-Stimulating Hormone and Luteinising Hormone, the active ingredient in Meriofert Pfs, is a gonadotropin presented as an injectable formulation for subcutaneous use. It treats infertility caused by anovulation and is employed in controlled ovarian stimulation for assisted reproductive technologies. GNH USA supplies Meriofert Pfs as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Meriofert Pfs is a gonadotropin used in reproductive medicine to stimulate ovarian function. - Infertility due to anovulation: induces follicular growth and ovulation in women with ovulatory dysfunction. - Controlled ovarian stimulation for assisted reproductive technologies: supports development of multiple follicles for IVF or ICSI cycles. - Hypogonadotropic hypogonadism: provides exogenous FSH and LH to initiate ovarian activity in patients with deficient endogenous gonadotropins.

Adverse reactions may occur with any injectable gonadotropin therapy.

Common Side Effects: - Injection site pain or erythema. - Mild abdominal discomfort or bloating. - Nausea or mild headache. - Transient ovarian hyperstimulation syndrome (mild). - Fatigue or dizziness.

Serious or Rare Side Effects: - Severe ovarian hyperstimulation syndrome with rapid weight gain, ascites, or respiratory distress. - Thromboembolic events such as deep‑vein thrombosis. - Allergic reactions including rash, urticaria, or anaphylaxis. - Multiple pregnancy (twins or higher order). - Ectopic pregnancy. - Severe abdominal pain indicating ovarian torsion.

Careful monitoring and patient assessment are essential when using Meriofert Pfs. - Baseline evaluation: perform ultrasound and hormone assays before initiating therapy. - Monitor for ovarian hyperstimulation: watch for abdominal distension, rapid weight gain, or shortness of breath. - Hypersensitivity: discontinue immediately if signs of allergic reaction appear. - Thromboembolic risk: assess history of clotting disorders and use caution. - Pregnancy testing: confirm patient is not pregnant prior to administration. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Potential drug interactions should be reviewed before prescribing Meriofert Pfs.

Major Interactions (Avoid): - Concurrent hCG for ovulation induction: may markedly increase risk of severe ovarian hyperstimulation. - Estrogen‑containing contraceptives used during treatment: can blunt gonadotropin response. - Thrombolytic agents: additive risk of clot formation.

Moderate Interactions (Monitor Closely): - Oral contraceptives prior to treatment: require appropriate wash‑out period to ensure efficacy. - GnRH analogues: timing may need adjustment to synchronize hormone peaks. - Medications affecting hepatic metabolism (e.g., certain antifungals): may alter hormone levels and require dose observation.